MaaT Pharma S.A. Actions Nom. EO-,1
- BID
2.68
- ASK
2.72
- 476 Units505 Units
- 07/23, 10:04:33 AM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
36.57%
Market Cap
-
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-1.95 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 2.68 G | 0 Units |
| PRICE DETERMINATION TIME | 07/23/2026 / 10:02:32 AM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 2.72 | 2.6 |
| PREV. DAY'S PRICE | 2.645 | (07/22) |
| CHANGE DAY BEFORE | +0.04 | 1.32 % |
| 52 WEEK HIGH / LOW | 8.18 (01/29) | 2.3 (07/01) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -1.73 | -2.21 | -1.95 | -1.73 | -1.54 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | - |
PRICE - BOOK RATIO | 3.96 | 10.76 | 50.39 | - | - |
PRICE - SALES RATIO | 35.60 | 32.34 | 16.94 | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A3C7A5 |
| ISIN | FR0012634822 |
| SYMBOL | 4RD |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | MAAT PHARMA S.A. EO-,1 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -0.38 % | -2.40 % | -50.28 % | -49.71 % | -36.57 % | -58.28 % | - | -41.09 % |
| HIGH | 2.83 | 3.00 | 7.78 | 8.18 | 8.18 | 9.82 | - | 8.18 |
| LOW | 2.50 | 2.30 | 2.30 | 2.30 | 2.30 | 2.30 | - | 2.30 |
Dividende
pro Aktie
MAAT PHARMA S.A. EO-,1 does not deliver dividend information
Company profile
Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. It engages to restore and modulate patient-microbiome symbiosis to improve survival in cancer. The company develops microbiome drug candidates: Microbiome Ecosystem Therapies which are high-diversity, high-richness, indication-specific products aiming to leverage the full functional diversity of a microbiome ecosystem. The company was founded by Herve Affagard, Joel Dore, Mohamad Mohty, Pierre Rimbaud and Pierre Belichard in 2014 and is headquartered in Lyon, France.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.